Transition Bio

The company develops a drug discovery platform that combines droplet microfluidics, cellular imaging, and machine learning to analyze biomolecular condensates. Its technology maps the impact of chemical matter on condensate systems at a molecular level to identify small-molecule inhibitors. The firm currently targets unmet needs in MYC-driven cancers and neurodegenerative diseases like ALS and FTD through internal programs and pharmaceutical collaborations.